Use of evidence-based meds increasing for STEMI, NSTEMI

February 12, 2013
Use of evidence-based meds increasing for STEMI, NSTEMI
Evidence-based therapies are increasingly being used to treat patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, according to research published in the Feb. 1 issue of The American Journal of Cardiology.

(HealthDay)—Evidence-based therapies are increasingly being used to treat patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), according to research published in the Feb. 1 issue of The American Journal of Cardiology.

Emily C. O'Brien, Ph.D., M.S.P.H., of the University of North Carolina at Chapel Hill, and colleagues used data from the Atherosclerosis Risk in Communities Community Surveillance Study to examine trends from 1987 to 2008 in the use of 10 medical therapies and procedures for STEMI and NSTEMI for 30,986 cases of definite or probable .

The researchers found that, for both STEMI and NSTEMI, increases were noted in the use of angiotensin-converting enzyme inhibitors (6.4 and 5.5 percent, respectively); antiplatelet therapy other than aspirin (5.0 and 3.7 percent); lipid-lowering drugs (4.5 and 3.0 percent); and beta-blockers (2.7 and 4.2 percent). Smaller increases were noted in the use of aspirin (1.2 and 1.9 percent) and heparin (0.8 and 1.7 percent). For patients with STEMI, use of thrombolytic agents and the number of procedures decreased.

"This is the first study to present long-term trends in in-hospital treatment for patients with STEMIs and those with NSTEMIs using validated clinical data," the authors write. "We observed an increase in the use of six of seven medications over the study period in patients with STEMIs and those with NSTEMIs."

Explore further: Aspirin still first-line therapy for unstable angina/NSTEMI

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Aspirin still first-line therapy for unstable angina/NSTEMI

July 17, 2012

(HealthDay) -- Aspirin is still the first line of therapy for patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and ticagrelor can be used in place of clopidogrel or prasugrel instead of aspirin ...

Multiple factors motivate no reperfusion in STEMI

August 2, 2012

(HealthDay) -- For patients presenting with ST-segment elevation myocardial infarction (STEMI), the decision for no reperfusion is usually multifactorial, with the most common factor being advanced age, according to a study ...

Non-smokers benefit most from smoking ban: study

August 27, 2012

After the smoking ban was introduced in Bremen, Germany, the rate of ST-elevation myocardial infarction (STEMI) diminished by 26% in non-smokers but remained almost constant in active smokers, according to research presented ...

Recommended for you

Female smokers face greatest risk for brain bleeds

July 21, 2016

Bleeding inside the lining of the brain (subarachnoid hemorrhage) is significantly more common among smokers, especially female smokers, than among people who do not smoke, according to new research in the American Heart ...

Global study shows stroke largely preventable

July 15, 2016

Ten risk factors that can be modified are responsible for nine of 10 strokes worldwide, but the ranking of those factors vary regionally, says a study led by researchers of the Population Health Research Institute (PHRI) ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.